Assertio Therapeutics Stock News

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Penny stocks to watch before November 2022 The post Best Penny Stocks To Buy? 4 To Watch Before November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products t

This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile pric

As stocks remain in a bear market, even the best penny stocks continue to trade at depressed price levels. With macro uncertainties like inflation, rising interest rates, and a possible recession stil

Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.

ASRT vs. UTHR: Which Stock Is the Better Value Option?

LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patien

Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

ASRT vs. STVN: Which Stock Is the Better Value Option?

Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.

These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market i

Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.